Medication adherence and resistant hypertension

Journal of Human Hypertension

Volumn 29, Issue 4, 2015, Pages 213-218

  Hyman, D J ^a   Pavlik, V ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; HUMAN; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT REFERRAL; PRIMARY MEDICAL CARE; RESISTANT HYPERTENSION; BLOOD PRESSURE; CLASSIFICATION; DRUG EFFECTS; DRUG RESISTANCE; HYPERTENSION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG RESISTANCE; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84924755264     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.73     Document Type: Article

References (44)

1. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2(6): 462-468.
2. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens 2014; 28(8): 463-468.
3. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013; 62(2): 218-225.
4. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M et al. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 2010; 28(12): 1097-1107.
5. Zeller A, Ramseier E, Teagtmeyer A, Battegay E. Patients' self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertens Res 2008; 31(11): 2037-2043.
6. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS et al. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1975; 1(7918): 1205-1207.
7. Steiner JF, Earnest MA. The language of medication-taking. Ann Intern Med 2000; 132(11): 926-930.
8. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25(9):2303-2310.
9. Fitzgerald AA, Powers JD, Ho PM, Maddox TM, Peterson PN, Allen LA et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail 2011; 17 (8): 664-669.
10. Oleen-Burkey MA, Dor A, Castelli-Haley J, Lage MJ. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. J Med Econ 2011; 14(6): 739-747.
11. Watanabe JH, Bounthavong M, Chen T. Revisiting the medication possession ratio threshold for adherence in lipid management. Curr Med Res Opin 2013; 29(3): 175-180.
12. Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R et al. Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care 2011; 49(5): 427-435.
13. Lowy A, Munk VC, Ong SH, Burnier M, Vrijens B, Tousset EP et al. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action. Int J Clin Pract 2011; 65(1): 41-53.
14. Chobanian AV. Impact of nonadherence to antihypertensive therapy. Circulation 2009; 120(16): 1558-1560.
15. Hill MN, Miller NH, Degeest S, Materson BJ, Black HR, Izzo JL Jr et al. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens 2011; 5(1): 56-63.
16. Mathes T, Pieper D, Antoine SL, Eikermann M. 50% adherence of patients suffering chronic conditions - where is the evidence? Ger Med Sci 2012; 10, Doc16.
17. Hyman DJ, Pavlik VN. Poor hypertension control: let's stop blaming the patients. Cleve Clin J Med 2002; 69(10): 793-799.
18. Moser M, Franklin SS. Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich) 2007; 9(5): 316-323.
19. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12(3): 239-245.
20. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med 2007; 120(1): 26-32.
21. Ndumele CD, Shaykevich S, Williams D, Hicks LS. Disparities in adherence to hypertensive care in urban ambulatory settings. J Health Care Poor Underserved 2010; 21(1): 132-143.
22. Bosworth HB, Dudley T, Olsen MK, Voils CI, Powers B, Goldstein MK et al. Racial differences in blood pressure control: potential explanatory factors. Am J Med 2006; 119(1): 70 e9-15.
23. Eze-Nliam CM, Thombs BD, Lima BB, Smith CG, Ziegelstein RC. The association of depression with adherence to antihypertensive medications: a systematic review. J Hypertens 2010; 28(9): 1785-1795.
24. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 16(2): CD000011.
25. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012; 157(11): 785-795.
26. Gwadry-Sridhar FH, Manias E, Lal L, Salas M, Hughes DA, Ratzki-Leewing A et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health 2013; 16(5): 863-871.
27. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376 (9756): 1903-1909.
28. Worthley SG1 TC, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y et al. Safety and ef ficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34, 2132-2140.
29. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35(9): 528-535.
30. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjonnaess E, Hjornholm U et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013; 62(3): 526-532.
31. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991; 151(9): 1786-1792.
32. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18(5 Pt 1): 619-626.
33. de Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar-Toledo JC, Moreno H et al. Intensive monitoring of adherence to treatment helps to identify 'true' resistant hypertension. J Clin Hypertens (Greenwich) 2009; 11(4): 183-191.
34. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011; 34(1): 87-90.
35. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4): 766-774.
36. Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol 2014; 63(8): 834-835.
37. Pandey A, Brinker S, Ayers C, Arbique D, Price A, Das Set al. Comparison of Morisky Medication Adherence Scale with Therapeutic drug monitoring in resistant hypertension. J Clin Hypertens 2013; 15: 1.
38. Bunker J, Callister W, Chang CL, Sever PS. How common is true resistant hypertension? J Hum Hypertens 2011; 25(2): 137-140.
39. Grassi D, O'Flaherty M, Pellizzari M, Bendersky M, Rodriguez P, Turri D et al. Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. J Clin Hypertens (Greenwich) 2008; 10(9): 662-667.
40. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet 1982; 1 (8265): 185-191.
41. Bunker J, Callister W, Chang C-L, Sever PS. How common is true resistant hypertension?. J Hum Hypertens 2011; 25 : 137-140.
42. Ruzicka M, McCormick B, Leenen FH, Froeschl M, Hiremath S. Adherence to blood pressure-lowering drugs and resistant hypertension: should trial of direct observation therapy be part of preassessment for renal denervation? Can J Cardiol 2013; 29(12): 1741 e1-3.
43. Rose AJ, Berlowitz DR, Manze M, Orner MB, Kressin NR. Intensifying therapy for hypertension despite suboptimal adherence. Hypertension 2009; 54 (3): 524-529.
44. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19(2): 335-341.